-+ 0.00%
-+ 0.00%
-+ 0.00%

Alzamend Neuro Q2 EPS $(0.30) Beats $(1.96) Estimate

Benzinga·12/09/2025 22:37:44
Listen to the news
Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(1.96) by 84.65 percent. This is a 91.69 percent increase over losses of $(3.61) per share from the same period last year.